May 27, 2015

Brian Marckx, CFA
bmarckx@zacks.com
Ph (312) 265-9474

Zacks Small-Cap Research

scr.zacks.com

10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606

Icad Inc (ICAD-NASDAQ)

ICAD: Company withdraws 2015 revenue guidance. Model, price target, rec remain under review

Current Recommendation	**Neutral**
Prior Recommendation	Outperform
Date of Last Change	05/07/2015
Current Price (05/26/15)	$4.47
Target Price	**$15.00**

OUTLOOK

iCAD's guidance, prior to this issue, was for 2015 revenue of $55M - $59M, or growth of 25% - 34%. This guidance was withdrawn on May 27th. We had been modeling 2015 total revenue of $57M, including $37.8M (+49%) of Therapy-related revenue prior to this issue, which came to light in early May.

We moved our investment recommendation from Buy to Neutral following the early May announcement. We are maintaining this Neutral rating for now based on the continued ambiguity of how significant this issue may be in terms of iCAD's financial performance. Our recommendation, price target and model all remain under review.

SUMMARY DATA

52-Week High	**$11.63**
52-Week Low	**$4.28**
One-Year Return (%)	**-31.89**
Beta	**1.22**
Average Daily Volume (sh)	**181,707**
Shares Outstanding (mil)	**16**
Market Capitalization ($mil)	**$74**
Short Interest Ratio (days)	**4.35**
Institutional Ownership (%)	**48**
Insider Ownership (%)	**15**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**11.8**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2015 Estimate	**N/A**
P/E using 2016 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**Above Avg.,**
Type of Stock	**Small-Value**
Industry	**Comp-Software**

ZACKS ESTIMATES

Revenue
(in '000 of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	8,520 A	9,667 A	12,572 A	13,165 A	43,924 A
2015	13220 A	13774 E	14827 E	15276 E	57,097 E
2016					74,846 E
2017					91,974 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2014	-$0.02 A	-$0.07 A	$0.02 A	-$0.01 A	-$0.07 A
2015	-$0.12 A	$0.03 E	$0.04 E	$0.05 E	$0.00 E
2016					$0.37 E
2017					$0.69 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW…

Skin Reimbursement Issue: Model, price target and rec remain under review. iCAD withdraws revenue guidance:

A memo issued by Noridian Healthcare Solutions, the Medicare contractor for the West coast, instructs physicians that CPT Code 0182T ("High dose rate electronic brachytherapy, per fraction") should not be used to bill for brachytherapy for non-melanoma skin cancer. Code 0182T was set up to be used to treat breast cancer. For non-melanoma skin cancer, effective June 8, 2015, Noridian says Code 17999 ("Unlisted procedure, skin, mucous membrane and subcutaneous tissue") should be used along with a code designating the location and size of the lesion.

We note that it has been industry standard to use 0182T to bill for non-melanoma skin cancer and an outstanding opinion by The American Society for Radiation Oncology (ASTRO) was that 0182T "is the appropriate code for outpatient services provided for electronic brachytherapy. It has mostly been used and reimbursed for breast cancer but is also being applied to gynecologic and other sites."

In a May 6th press release iCAD noted that they and others in the industry are addressing the issue and have requested clarification from CMS and Noridian. The company also stated at the time that "there is insufficient clarification of the reimbursement matter to assess the potential impact that this matter could have on the Company's guidance for 2015. Any significant changes in CPT reimbursement from current levels could have a material impact on the Company's revenues."

iCAD's guidance, prior to this issue, was for 2015 revenue of $55M - $59M, or growth of 25% - 34%. On May 27th the company announced that they are now withdrawing that guidance due to this reimbursement issue and further noted that they are, "proactively working to gain clarity on the issue and will provide an update on reimbursement when appropriate".

We had been modeling 2015 total revenue of $57M, including $37.8M (+49%) of Therapy-related revenue prior to this issue. As a result of this Noridian announcement, we put our model and price target under review – where they still remain. Based on the ambiguity of how significant this issue may be in terms of iCAD's financial performance, we also moved our investment recommendation from Buy to Hold.

We will update our model, price target and investment recommendation, if appropriate, when more information becomes available.

FINANCIAL MODEL

iCAD Inc.

Model is currently under review

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



© Copyright 2015, Zacks Investment Research. All Rights Reserved.

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brian Marckx, CFA, CFA, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1119 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 24.2%, Hold/Neutral- 59.2%, Sell/Underperform – 14.0%. Data is as of midnight on the business day immediately prior to this publication.